Institute Activities and Advances
The Effects of FMR1 Premutations in Adults and Children
In 2001, researchers supported by the Intellectual and Developmental Diseases Branch (IDDB) discovered FXTAS.
The same NICHD-supported researchers have found that FXTAS is associated with other conditions. For example, sleep apnea is three times more common in people with FXTAS than in the general population. People with FXTAS are also at a higher lifetime risk of mood disorders, including major depressive disorder, anxiety disorder, and post-traumatic stress disorder. In addition, men with FXTAS are more likely to have high blood pressure than men without the FMR1
premutation. (Men with the premutation who don’t have FXTAS are not at increased hypertension risk.) (Sources: Hamlin, A., et al. (2011). American Journal of Medical Genetics
. PMID: 21932336
; Bourgeois, J. A., et al. (2011). Journal of Clinical Psychiatry
. PMID: 20816038
; and Hamlin, A., et al. (2012). American Journal of Medical Genetics. Part A. PMID: 22528549
Researchers are studying the protective factors in carriers of FXTAS and the proteins involved in the pathogenesis to determine ways to prevent or reverse the process. They have also found early neurodevelopmental abnormalities in premutation mice, leading to the question of whether it is a lifelong process, and providing hope for the development of early intervention. (Source: Hagerman, P. J., (2012). Current gaps in understanding the molecular basis of FXTAS. Tremor and Other Hyperkinetic Movements; New York: 63.)
Some people with FMR1 premutations experience symptoms in childhood. For example, boys with FMR1 premutations have a higher risk of seizures, compared with boys who do not have premutations. Also, boys who had seizures were also more likely to have an autism spectrum disorder. (Source: Chonchaiya, W. (2012). Human Genetics. PMID: 22001913)
Further research supported by the IDDB aims to explore how the FMR1 premutation affects the development of children and the neurological health of adults. This research includes a study of 500 adults (age 40 years and older) and 150 boys (ages 8 to 16). In the boys, studies will focus on attention deficit hyperactivity disorder and social deficits, including autism spectrum disorder. In the adults, researchers will focus on age-related changes.1
Better Diagnostics and Screening Tools for Fragile X and Premutations
Several NICHD-supported research groups are seeking ways to better diagnose and screen for fragile X mutations and premutations. One potential screening method currently being tested would analyze a small drop of blood on a paper card to detect fragile X syndrome in newborns.
Early physical recognition of the characteristics of fragile X syndrome is difficult, and this method uses new technologies that have been developed that can detect all categories of fragile X alleles, including full mutation expansions.2
Other Activities and Advances
To achieve its research goals for fragile X syndrome and associated disorders, the NICHD is involved with a variety of activities. Some of these activities are managed through the components listed above; others are part of NIH-wide or collaborative efforts in which the NICHD participates.
- The NICHD's IDDB funds three Fragile X Syndrome Research Centers (FXSRCs). The centers are geared toward stimulating multidisciplinary, multi-institutional research and translating basic research findings into clinical practice.
- The NIH Fragile X Research Coordinating Group, led by the NICHD, includes nine institutes with research interests on different aspects of fragile X or its associated disorders. The group consulted with outside experts and published a long-term agenda for FMR1 research, called the NIH Research Plan on Fragile X Syndrome and Associated Disorders, in 2008. Finding treatments and supporting families impacted by fragile X and its related disorders are major goals of the plan.
In addition, the plan supports a focus on defining the full range of clinical effects of the FMR1 premutation, its natural course, and the identification of the earliest markers of FXTAS disease in order to facilitate diagnosis and the proper management or prevention of problems experienced by those who have a premutation. This could have a substantial impact on management and genetic counseling for a large number of individuals in the general population.
The group recently issued a Request for Information (RFI) to get feedback on the NIH Research Plan and to seek creative, concrete suggestions from scientific experts in the research and clinical communities, representatives for affected individuals and family members, and pertinent federal agencies. For details, visit http://grants.nih.gov/grants/guide/notice-files/NOT-HD-12-012.html.3
- Hagerman, R. J. Genotype-phenotype relationships in fragile X families. Retrieved August 21, 2012, from http://projectreporter.nih.gov/project_info_description.cfm?aid=8064264&icde=11603567 [top]
- Latham, G. J. Enabling use of blood spot cards for accurate high-throughput fragile X screening. Retrieved August 21, 2012, from http://projectreporter.nih.gov/project_info_description.cfm?aid=8124769&icde=11603103 [top]
- National Institutes of Health. (2008). National Institutes of Health Research Plan on Fragile X Syndrome And Associated Disorders. Retrieved May 31, 2012, from http://www.nichd.nih.gov/publications/pubs/upload/NIH_Research_Plan_on_Fragile_X_and_Assoc_Disorders-06-2009.pdf (PDF - 440 KB) [top]